Physician profile
Mir Hashimi
NPI 1942253893
$24,486.02
in general payments reported to CMS, 2019-2025
24 companies · $599 in 2025
The $599 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $863 · 2020: $5,721 · 2021: $11K · 2022: $872 · 2023: $2,174 · 2024: $2,977 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,899 · Food and Beverage: $2,851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,898.97 |
| Food and Beverage | $2,850.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $21,019.27 | 2019-2025 | Mitraclip, Aveir, Jot Dx |
| Boston Scientific Corporation | $1,385.81 | 2019-2025 | Farapulse |
| Medtronic, INC. | $716.56 | 2021-2025 | Onyx Frontier, Symplicity G3, Corevalve Evolut R |
| Janssen Pharmaceuticals, INC | $271.55 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $157.74 | 2024-2025 | Ozempic, Rybelsus |
| Ge Healthcare | $116.10 | 2023 | |
| Zimmer Biomet Holdings, INC. | $102.99 | 2025 | Ribfix Blu Advantage |
| Medtronic Vascular, INC. | $101.10 | 2019-2020 | |
| Heartflow, INC. | $94.38 | 2022 | |
| Amgen INC. | $62.13 | 2019-2023 | Repatha |
| Cvrx, INC. | $58.93 | 2024 | Barostim Neo System |
| Edwards Lifesciences Corporation | $56.27 | 2023 | |
| Penumbra, INC. | $47.74 | 2025 | Indigo System, Penumbra System |
| Kiniksa Pharmaceuticals International, Plc | $46.84 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.01 | 2022-2023 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $40.37 | 2024 | Impella |
| Atricure, INC. | $36.36 | 2021-2024 | |
| Pfizer INC. | $31.56 | 2024 | |
| Merck Sharp & Dohme LLC | $27.86 | 2023-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.96 | 2021 | |
| Esperion Therapeutics, INC. | $14.88 | 2023 | Nexletol |
| Philips North America LLC | $13.61 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.32 | 2019 | |
| Z-Medica, LLC | $10.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mir Hashimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.